There have been great advances in the quest for new chemicals with possible uses in the field of science. DNSP-11 is a promising research molecule because of its potential to protect mitochondria, the cellular powerhouse, both in vitro and in vivo.
The journey of DNSP-11 began with the astute predictions of Dr. John Glass, alongside independent findings by a team at the University of Helsinki. Through in silico studies and meticulous analysis of post-translational cleavage pathways, these researchers identified specific peptide sequences within the preproGDNF protein, which serves as the foundation for DNSP-11.
DNSP-11 has been shown to protect mitochondria in a number of different cellular models, adding to its list of distinctive features. DNSP-11 differs from GDNF in an intriguing way: it protects mitochondria from the cytotoxicity caused by staurosporin and gramicidin. Given the importance of mitochondrial malfunction in the etiology of Parkinson’s disease, this kind of defense is essential.[R]
Key Features of DNSP-11
RCD.Bio offers DNSP-11 with the following specifications:
- A purity of 98%, verified by third-party laboratory testing.
- Available in Peptide Form: 5mg
How DNSP-11 Works
The dopaminergic system in PD is thought to be restored and protected by DNSP-11. Evidence for DNSP-11’s potential in this area comes from numerous studies measuring a wide range of physiological indicators, health and behavior observations, histological analyses, neurochemical assays, and apomorphine-induced rotation measurements.
The major factor contributing to motor impairments in PD is the loss of striatal dopamine content. DNSP-11, by promoting neuroprotection and restoration, has the potential to counteract this dopamine depletion. While the exact mechanism of DNSP-11’s action is still being explored, it is hypothesized that DNSP-11 enhances the synthesis, release, or availability of dopamine in the striatum.
DNSP-11’s actions are consistent with the goals of current PD treatments, which are to enhance dopamine levels in the striatum. Dopamine-enhancing drugs, such as L-DOPA and monoamine oxidase (MAO) inhibitors, are reported to reduce motor symptoms. DNSP-11 may operate via comparable mechanisms, suggesting it may be useful as an alternative to or in conjunction with current therapies.[R]
The scientific basis behind the benefits of DNSP-11
Numerous research investigations and trials on animals suggest that DNSP-11 may have a number of benefits.
DNSP-11 on Behavior
In animal studies, a single injection of DNSP-11 into the substantia nigra of normal adult rats resulted in its rapid uptake by neurons. This uptake led to increased resting levels of dopamine and its metabolites for an extended period of up to 28 days. Notably, DNSP-11 exhibited a significant improvement in apomorphine-induced rotational behavior, a common behavioral measure in PD research. It also increased dopamine and dopamine metabolite tissue levels in the substantia nigra, highlighting its potential as a therapeutic option for PD.[R]
DNSP-11 holds significant promise for the treatment of Parkinson’s disease. Its ability to support the survival and growth of dopamine neurons, enhance dopamine levels, and improve behavioral outcomes in animal models makes it an attractive candidate for further research and development.
DNSP-11 on Parkinson’s disease
Parkinson’s disease (PD) is characterized by the loss of dopaminergic neurons in the substantia nigra (SN) and subsequent dopamine (DA) depletion in the striatum. Glial cell line-derived neurotrophic factor (GDNF) has shown promising effects in restoring and protecting DA neurons in various studies involving rats, non-human primates, and potentially humans. However, the therapeutic application of GDNF has been limited by its large size and chemical structure, which restrict its diffusion to target areas. To overcome this challenge, researchers have explored smaller peptides derived from the prosequence, including dopamine neuron stimulating peptide-5 (DNSP-5).
DNSP-5 (30 g) given unilaterally to the SN elevated extracellular levels of dopamine (DA) by almost 66% compared to the control vehicle in in vivo tests. Three of the DA metabolites, 3,4-dihydroxyphenylacetic acid, homovanillic acid, and vanillin, did not change in concentration. These results underline the importance of DNSP-5’s capacity to increase DA levels in the striatum for the treatment of PD symptoms. In addition, DNSP-5 protected a neuronal cell line from the cytotoxicity caused by staurosporine. This data provides support for the idea that DNSP-5 exhibits neurotrophic-type qualities that may be useful in the treatment of neurodegenerative illnesses like PD. [R]
Further research is required to comprehend the effect of dopamine neuron function on the central dopamine system in Parkinson’s disease.
DNSP-11 on Dopamine
Dopamine neuron stimulating peptide-11 (DNSP-11) and other short peptides generated from the GDNF proregion have been shown to have neurological effects in recent studies. High-speed chronoamperometry was used to investigate the effects of DNSP-11 on DA release in the striatum at 1, 2, and 4 weeks post-treatment. Two weeks following therapy, researchers noticed an increase in potassium-evoked DA release in certain striatal areas. These results suggest that DNSP-11 may have a localized effect on DA release patterns in the brain. [R] More study is necessary in order to understand the effect that DNSP-11 dopamine has.
The information presented here is for educational purposes only and should not be construed as medical advice. DNSP-11 is intended for laboratory research use only and is not intended for human consumption.
Potential side effects
DNSP-11, which affects dopamine levels, can lead to various side effects. When dopamine levels are elevated, both in the brain and the body, it can cause a range of potential adverse effects. These include neurological effects like confusion, hallucinations, anxiety, increased sex drive, and drowsiness. Peripheral side effects may be more severe and can include heart rhythm irregularities, low blood pressure, breathing problems, stomach bleeding, nausea, and, in rare cases, hair loss.[R] it is worth noting that further research is required to ascertain the frequency and severity of these side effects of sudden snap recipients of DNSP-11.
Where Can I Buy DNSP-11 Online?
RCD.bio offers DNSP-11 for laboratory and research use only.
When buying DNSP-11, it is important to choose a reputable seller who provides quality and snap benefits of DNSP-11. At RCD.bio, each product is accompanied by a third-party-issued Certificate of Analysis showing the identification, purity, and concentration of our product.
As researchers explore the potential of DNSP-11, it is vital to ensure adherence to guidelines and prioritize the well-being of individuals involved in the research, as well as considering the role of DNSP-11 in the federal program.
DNSP-11 is a promising research molecule that protects mitochondria and shows potential for treating Parkinson’s disease. It enhances dopamine levels and improves behavioral outcomes in animal studies. DNSP-11 is derived from GDNF and influences dopamine release in specific brain regions. However, caution is advised as it may cause side effects related to dopamine levels. DNSP-11 is available for laboratory use only. Further research is needed to fully understand DNSP-11’s effectiveness and safety in treating PD.
Please take note of the scientific applications of this product and carefully read our Terms and Conditions before making a purchase from RCD.bio. By completing your order and submitting payment, you agree to abide by our Terms and Conditions. Please be aware that the product packaging may differ slightly from the images displayed on our website.
If for any reason you are not completely satisfied with the product you receive, please contact us at [email protected]. Our team is dedicated to ensuring customer satisfaction and will be happy to assist you.
PLEASE NOTE: All products offered by RCD.bio are strictly intended for laboratory and research purposes only. They are not intended for use on animals or humans.